Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: A phase I study

被引：0
|
作者：
Siegel, D. S. [1 ,2 ,3 ,4 ,5 ,6 ]
Weber, D. M. [1 ,2 ,3 ,4 ,5 ,6 ]
Mitsiades, C. S. [1 ,2 ,3 ,4 ,5 ,6 ]
Dimopoulos, M. A. [1 ,2 ,3 ,4 ,5 ,6 ]
Harousseau, J. L. [1 ,2 ,3 ,4 ,5 ,6 ]
Rizvi, S. [1 ,2 ,3 ,4 ,5 ,6 ]
Howe, J. [1 ,2 ,3 ,4 ,5 ,6 ]
Reiser, D. [1 ,2 ,3 ,4 ,5 ,6 ]
Anderson, K. C. [1 ,2 ,3 ,4 ,5 ,6 ]
Richardson, P. G. [1 ,2 ,3 ,4 ,5 ,6 ]
机构：
[1] Hackensack Univ, Med Ctr, Hackensack, NJ USA
[2] MD Anderson Canc Ctr, Houston, TX USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] Univ Athens, Sch Med, GR-11527 Athens, Greece
[5] Ctr Rene Gauducheau, Saint Herblain, France
[6] Merck & Co Inc, Upper Gwynedd, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8586
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study
    Iida, Shinsuke
    Nagai, Hirokazu
    Kinoshita, Gen
    Miyoshi, Masafumi
    Robbins, Michael
    Pandya, Dimple
    Bleickardt, Eric
    Chou, Takaaki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (03) : 326 - 334
  • [42] Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.
    Ocio, Enrique M.
    Mateos, Maria-Victoria
    Prosper, Felipe
    Martin, Jesus
    Rocafiguera, Albert Oriol
    Jarque, Isidro
    Iglesias, Rebeca
    Motlloo, Cristina
    Sole, Maria
    Rodriguez-Otero, Paula
    Martinez, Sara
    Fernandez-Garcia, Eva
    Michot, Jean-Marie
    Soto-Matos, Arturo
    Diaz-Pavon, Jose Rodriguez
    Ribrag, Vincent
    Miguel, Jesus San
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [43] Phase I Results of Perifosine (KRX-0401) in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (MM).
    Jakubowiak, Andrzej
    Richardson, Paul
    Zimmerman, Todd M.
    Alsina, Melissa
    Kaufman, Jonathan L.
    Harvey, Colleen
    Brozo, Christine
    Kendall, Tara
    McAllister, Amanda
    Hideshima, Teru
    Sportelli, Peter
    Gardner, Lesa
    Anderson, Kenneth C.
    Giusti, Kathy
    BLOOD, 2008, 112 (11) : 1264 - 1265
  • [44] Biomarker Correlation with Outcomes in Patients with Relapsed or Refractory Multiple Myeloma on a Phase I Study of Everolimus in Combination with Lenalidomide
    Yee, Andrew J.
    Mahindra, Anuj K.
    Richardson, Paul G.
    Cirstea, Diana D.
    Scullen, Tyler A.
    Rodig, Scott J.
    Hideshima, Teru
    Hari, Parameswaran
    Laubach, Jacob P.
    Ghobrial, Irene M.
    Schlossman, Robert
    Munshi, Nikhil C.
    Weller, Edie A.
    Anderson, Kenneth C.
    Raje, Noopur S.
    BLOOD, 2011, 118 (21) : 1696 - 1697
  • [45] A Phase I Study of Ruxolitinib, Lenalidomide, and Steroids for Patients with Relapsed/Refractory Multiple Myeloma
    Berenson, James R.
    To, Jennifer
    Spektor, Tanya M.
    Martinez, Daisy
    Turner, Carley
    Sanchez, Armando
    Ghermezi, Matthew
    Eades, Benjamin M.
    Swift, Regina A.
    Schwartz, Gary
    Eshaghian, Shahrooz
    Stampleman, Laura
    Moss, Robert A.
    Lim, Stephen
    Vescio, Robert
    CLINICAL CANCER RESEARCH, 2020, 26 (10) : 2346 - 2353
  • [46] Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study
    Voorhees, Peter M.
    Gasparetto, Cristina
    Richards, Kristy L.
    Garcia, Reynaldo
    Strader, John S.
    Ferraro, Madlyn
    MacLean, Jennifer
    Winans, Diane
    Moore, Dominic T.
    Dodd, Andrew
    Foster, Matthew C.
    Gabriel, Don A.
    Shea, Thomas C.
    Serody, Jonathan
    van Deventer, Hendrik W.
    Rizvi, Syed
    Orlowski, Robert Z.
    Hurd, David D.
    BLOOD, 2009, 114 (22) : 129 - 130
  • [47] Results of a Phase I Study of Vorinostat In Combination with Pegylated Liposomal Doxorubicin and Bortezomib In Patients with Relapsed/Refractory Multiple Myeloma
    Voorhees, Peter M.
    Gasparetto, Cristina
    Osman, Keren
    Richards, Kristy
    Ferraro, Madlyn
    Garcia, Reynaldo
    MacLean, Jennifer
    Winans, Diane
    Moore, Dominic
    Strader, John
    Orlowski, Robert Z.
    Hurd, David Duane
    BLOOD, 2010, 116 (21) : 815 - 816
  • [48] Phase I Trial of Perifosine, Lenalidomide, and Dexamethasone in Relapsed or Refractory Myeloma
    Jakubowiak, A. J.
    Hideshima, T.
    Sportelli, P.
    Gardner, L.
    Giusti, K.
    Richardson, P. G.
    Zimmerman, T.
    Alsina, M.
    Kaufman, J.
    Brozo, C.
    Kendall, T.
    McAllister, A.
    Harvey, C.
    Anderson, K. C.
    CLINICAL LYMPHOMA & MYELOMA, 2009, 9 : S56 - S57
  • [49] A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma
    Yoshiaki Ogawa
    Michinori Ogura
    Kensei Tobinai
    Kiyoshi Ando
    Tatsuya Suzuki
    Takashi Watanabe
    Ken Ohmachi
    Toshiki Uchida
    Mary E. Hanson
    Yoshinobu Tanaka
    Yasuhiro Koh
    Takashi Shimamoto
    Tomomitsu Hotta
    International Journal of Hematology, 2016, 103 : 25 - 33
  • [50] A phase I study of vorinostat combined with bortezomib in Japanese patients with relapsed or refractory multiple myeloma
    Ogawa, Yoshiaki
    Ogura, Michinori
    Tobinai, Kensei
    Ando, Kiyoshi
    Suzuki, Tatsuya
    Watanabe, Takashi
    Ohmachi, Ken
    Uchida, Toshiki
    Hanson, Mary E.
    Tanaka, Yoshinobu
    Koh, Yasuhiro
    Shimamoto, Takashi
    Hotta, Tomomitsu
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2016, 103 (01) : 25 - 33
12345